REFERENCES
- Briasoulis E., Pavlidis N. Cancer of unknown primary origin. Oncologist 1997; 2(3)142–152
- American Cancer Society. Detailed guide: what are the key statistics for cancer of unknown primary, http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_cancer_of_unknown_primary_58.asp?sitearea= January 2004 update. Available online at: [accessed June 15, 2005]
- Blaszyk H., Hartmann A., Bjornsson J. Cancer of unknown primary: clinicopathologic correlations. APMIS 2003; 111(12)1089–1094
- Hainsworth J. D., Johnson D. H., Greco F. A. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J. Clin. Oncol. 1992; 10(6)912–922
- Hanauske A. R., Clark G. M., Von Hoff D. D. Adenocarcinoma of unknown primary: a retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system. Invest. New Drugs 1995; 13(1)43–49
- Greco F. A., Hainsworth J. D. The evolving role of paclitaxel for patients with carcinoma of unknown primary site. Sem. Oncolog. 1999; 26(1)129–133, Suppl. 2
- Hainsworth J. D., Erland J. B., Kalman L. A. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J. Clin. Oncol. 1997; 15(6)2385–2393
- Briasoulis E., Kalafonos H., Bafaloukas D. Carboplatin plus paclitaxel in unknown primary carcinoma, a phase II Helenic Cooperative Oncology Group Study. J. Clin. Oncol. 2000; 18(17)3101–3107
- Greco F. A., Burris H. A., 3rd, Litchy S. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J. Clin. Oncol. 2002; 20(6)1651–1656
- Greco F. A., Gray J., Burris H. A., 3rd, Erland J. B., Morrissey L. H., Hainsworth J. D. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J. 2001; 7(3)203–212
- Culine S., Lortholary A., Voigt J. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J. Clin. Oncol. 2003; 21(18)3479–3482
- WHO handbook for reporting results of cancer treatment. 1979, Geneva (Switzerland): World Health Organization Offset Publication No. 48
- Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
- Culine S., Kramar A., Saghatchian M. Development and validation of a prognsotic model to predict the length of survival in patients with carcinomas of an unknown primary site. J. Clin. Oncol. 2002; 20(24)4679–4683